Artificial Intelligence

Building trust: The crucial bridge between AI and healthcare

Chiara Vona — Fri, 15 Dec 2023 08:58:16 +0000

Building trust: The crucial bridge between AI and healthcare

Colin Lake, Digital Care Transformation Neurology

Chiara Vona Fri 15/12/2023 - 09:58

For three decades, we’ve been committed to people living with epilepsy and their families, surrounding the patient and caregiver through every step of their care journey. In the ever-evolving healthcare landscape, Artificial Intelligence (AI) and the digitalization of healthcare, is set to create new standards and advancements in care for people living with epilepsy and rare epileptic syndromes. This digitalization is revolutionizing the way we understand and approach these complex neurological disorders, with AI helping us to push the boundaries of healthcare and drug development by enabling us to support more precise diagnoses, detect patterns and trends, and aid disease prevention.

However, the successful integration of AI into healthcare relies heavily on a foundation of trust – trust from the public, medical professionals, and caregivers. We understand that this trust has improved drastically over the past few years, with events like COVID-19 necessitating remote digital healthcare, but there remains a distrust in the public domain. The main questions we are being asked are “Where is my data being used?”, “Who is looking at my data?” and “How will my data be used?”

Because of this, it is our role as experts in neurology to address these questions and be transparent. While the challenge of trust is not specific to ��ֳ� but industry-wide, we are continuously working to build that trust with patients, caregivers, and medical professionals.
Collaboration and partnerships are an essential way to build trust, and we know that we cannot do this alone. We must turn to expert digital partners, such as Microsoft, to support us on this journey. The continuous work we do together establishes a strong foundation for the future and landscape of neurology.

One example of how we’re using AI is the development of wearable technology – being able to track movement disorders not only helps patients but also increases our own understanding of how they manage their condition. The development of this technology also allows us to monitor patient data in real-time but has also enabled us to engage with a larger, more diverse patient pool within remote clinical trials. We can collect more data and ensure we secure better equity around patients, effectively reaching underserved populations.

Another area we are currently exploring is the use of ‘Digital Twins’ - a digital copy - to accurately reflect a physical human brain. The use of this modeling technology could assist in identifying the pattern of symptomatic behaviors such as seizures and, in principle, help medical professionals to individualize treatment based on the simulated behavior to predict how a specific patient might react to treatment.

Given the digital landscape is evolving rapidly, we must keep up with the pace and constantly look at ways we can digitalize our offering to secure a better outcome for our patients. It has never been more important to provide the best outcome for a patient across their entire journey and digital technology can help us achieve that.

innovation

Comment:

Posted by healthcrmai, 11 April 2025

Great article! We always appreciate valuable insights like these. Thanks for sharing!

685 Likes

Committed to drug discovery innovation

Vanco Vlastimil (��ֳ� S.A.) — Tue, 19 Sep 2023 08:45:55 +0000

Committed to drug discovery innovation

Alexander Hillisch, Global Computer-aided drug design

Vanco Vlastimi… Tue 19/09/2023 - 10:45

This week ��ֳ� joined the OpenFold Artificial Intelligence (AI) Research Consortium. Joining this consortium reinforces our commitment to innovation in drug discovery and an aim to address the unmet medical needs of patients.

Participation in the consortium will help to enhance digital molecular design at ��ֳ�, using the power of deep learning, whilst contributing to the advancement of open-source research to the wider scientific community. Collaboration and partnerships are key to accelerate the impact of new technologies particularly in the rapidly evolving fields of artificial intelligence and computer-aided drug design (CADD).

The application of digital design at the molecular level has already enabled the discovery of some of our biologics-based treatments at ��ֳ�. Joining the OpenFold consortium will help ��ֳ� to further contribute to the understanding of how and why molecules bind, in a collaborative, pre-competitive environment. The consortium will aid accurate state-of-the-art AI based structure prediction and assessment of interactions between protein:protein and protein:small molecules to deliver not only open science and innovation but also assist the design of novel treatments.

You can read the press release here.

innovation

Innovation OpenFold Artificial Intelligence Drug discovery CADD Computer-aided drug design

Comment:

Posted by hubertj0832737…, 19 September 2023

Hi there to all, the contents existing at this website are in fact remarkable for people knowledge, well, keep up the good work fellows.

552 Likes

Partnering for Greater Impact with Microsoft in R&D

Vanco Vlastimil (��ֳ� S.A.) — Wed, 23 Feb 2022 10:02:30 +0000

Partnering for Greater Impact with Microsoft in R&D

Wang Yuan, Data and Translational Sciences

Vanco Vlastimi… Wed 23/02/2022 - 11:02

At ��ֳ�, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs.

In drug discovery, specifically, we’re using AI methodologies to enhance ��ֳ�’s data science strategy. We want to increase the impact of a treatment through a deeper understanding of the biological causes of the disease and systematically provide better research data-driven insights to enable the faster discovery of therapeutic molecules.

To aid us in this research, we announced an expanded multi-year, strategic collaboration to combine Microsoft’s computational services, cloud, and AI with ��ֳ�’s drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets or multi-modal unstructured information, Microsoft’s platform can support ��ֳ�’s scientists, including its data scientists, to discover new medicines in a more efficient and innovative way.

Our first use case is related to our Targeted Protein Degradation platform, where we are using AI-enabled workflows to better and more quickly collect information around disease-relevant biology and potential molecules of therapeutic value. Supported by Microsoft’s data science capabilities, our researchers aspire to ask questions on a whole new scale, and to review and compare millions of scientific literature in a more efficient manner.

By using advanced analytics, researchers can analyze and synthesize decades of scientific knowledge faster, with better interconnectivity to uncover underlying trends. Based on such extensive knowledge, scientists can make more informed data-driven decisions in the search of new medicines.

In addition to the scientific journey we have started here, this collaboration is also a cultural journey, exposing our industry to the novel solutions and enabling technologies provided by our partners in the technology sector, and inviting our partners to tackle more scientific challenges we face.

Watch the video now.

We are deepening our impact for people living with severe diseases by finding the right medicine for the right patient at the right time and working to further the good of society with a comprehensive collaboration strategy to support innovation. We are forging new relationships with leading researchers from academia and organizations, like Microsoft, to address some of today’s biggest healthcare challenges.

about ucb

Microsoft AI Artificial Intelligence Drug discovery R&D

982 Likes

How AI is accelerating the development of new treatments for specific patient populations

eCMSadmin — Mon, 28 Jun 2021 00:00:00 +0000

How AI is accelerating the development of new treatments for specific patient populations

Herman de Prins, Information Technology

eCMSadmin Mon 28/06/2021 - 02:00

Make sure to listen to the full episode on any of the following platforms:

Artificial Intelligence (AI) will only grow in importance for the health and life science industry. We already see it as really valuable for helping us develop new treatments for people – and faster. Before I delve into the possibilities and challenges that AI brings, let me take you back to when I first became interested in AI.

Watson intrigued me
I remember seeing one specific episode of the Jeopardy! game show on TV at some point during 2011. IBM’s Watson computer beat America’s best players. That intrigued me. Just a month later, I got chatting to John Kelly – IBM’s Head of Research and father of Watson – at a conference. We talked excitedly about the possibilities of AI.

By the time a few months had passed, we had already built a joint AI project. Watson used cognitive computing – specifically patient similarity analytics and real-world data – to predict potential outcomes and identify personalized care for people living with epilepsy.

We quickly saw incredible enthusiasm for AI grow across ��ֳ�. As a result, we applied for a couple of patents, primarily as recognition of our employees’ great work.

We wanted to bring every ��ֳ� employee with us on our AI journey. So, in 2016, we created a technology practice, a practice that later became our ‘DataMinds and DigiMinds program’. The program helped increase digital understanding and capabilities at ��ֳ�, specifically around data literacy and digital business transformation.

I put the fantastic number of AI initiatives we’re seeing at ��ֳ� today down to that program, initiatives that span the whole value chain.

Amazing AI initiatives
You only have to look at our Moonshot initiative, a joint initiative we worked on with Microsoft last summer. Combining our AI algorithms with Microsoft’s massive compute power allowed us to research potential treatments for COVID at an accelerated speed. Thanks to AI, we completed research that would typically take six months in just three days.

More generally, I’m convinced that AI can play a significant role in developing the COVID vaccines and potential treatments we see today. But that’s not specific to COVID; I’m seeing the whole pharma industry embracing AI.

Looking to the future, I believe there will be massive – and sometimes scary – advances with AI on many fronts. Take GPT-3, a language model that uses deep learning to produce human-like text. GPT-3 already uses 175 billion machine learning parameters, ten times as much as the technology we mainly see today. Putting such capacity and capability into a robot is just huge.

Proceeding with caution
I also see AI becoming more embedded in technology products in such a way that it won’t always be obvious what’s AI and what’s not. So there needs to be a set of rules around that, and the European Commission is working on those.

Other significant issues around AI need to be addressed, including ethical issues, data privacy issues and bias in both the algorithm and the data. Every dataset, every algorithm inherently has a bias, which means every AI initiative is based on something biased. You need to be aware of it to overcome it, and we do that by including bias as one of the elements we look at in our ethical reviews.

My biggest interest in AI is what it can help us achieve in R&D, primarily in research. Why? Because AI in research is helping us create a lot of value for our patients. AI is helping us find better treatments for specific patient populations – and do that faster than before.

innovation

AI Research and Development Artificial Intelligence

879 Likes

Artificial Intelligence

Building trust: The crucial bridge between AI and healthcare

Leave a Comment

Committed to drug discovery innovation

Leave a Comment

Partnering for Greater Impact with Microsoft in R&D

Leave a Comment

How AI is accelerating the development of new treatments for specific patient populations

Leave a Comment